Table 1. Baseline patient characteristics.
| Characteristic | Sunitinib (n=1059) |
|---|---|
| Median (range) age, years |
60 (24–87) |
| Male/female, % |
70/30 |
|
Ethnic origin, % | |
| White | 83 |
| Non-white | 13 |
| Missing |
4 |
|
ECOG PS, % | |
| 0 | 61 |
| 1 | 37 |
| 2 |
2 |
|
Risk factors based on published MSKCC data, %a | |
| 0 (favourable) | 39 |
| 1–2 (intermediate) | 39 |
| ⩾3 (poor) | 4 |
| Missing |
17 |
|
Histology, % | |
| Clear cell | 97 |
| Other | 3 |
| Missing |
<1 |
| Prior nephrectomy, %b |
79 |
|
Sites of metastasis, % | |
| Lung | 77 |
| Liver | 23 |
| Bone | 29 |
Abbreviations: ECOG PS=Eastern Cooperative Oncology Group performance status; MSKCC=Memorial Sloan-Kettering Cancer Center.
a
Includes low serum haemoglobin level; elevated corrected serum calcium level; elevated serum lactate dehydrogenase level; poor performance status; and interval of <1 year between diagnosis and sunitinib treatment (Motzer et al, 2002).
b
Nephrectomy status is missing for 57 patients (4%).